SYNGENE.NS
SYNGENE.NS
INE398R01022
SYNGENE INTERNATIONAL LTD
Loading chart...

Company Profile

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Related stocks

METROPOLIS.NS
METROPOLIS.NS • India
METROPOLIS HEALTHCARE LTD
529.25 INR
1.13B USD 1Y +4.2%
VIJAYA.NS
VIJAYA.NS • India
VIJAYA DIAGNOSTIC CEN LTD
1,436.6 INR
1.53B USD 1Y +44.5%
SAILIFE.NS
SAILIFE.NS • India
SAI LIFE SCIENCES LIMITED
1,487.9 INR
3.27B USD 1Y +74.7%
LALPATHLAB.NS
LALPATHLAB.NS • India
DR. LAL PATH LABS LTD.
1,933.6 INR
3.34B USD 1Y +23.3%
THYROCARE.BO
THYROCARE.BO • India
Thyrocare Technologies Limited
499 INR
820.66M USD 1Y +22%
4544.T
4544.T • Japan
H.U. GROUP HLDGS INC
3,580 JPY
1.23B USD 1Y -4%
300685.SZ
300685.SZ • China
AMOYDX
20.3 CNY
1.18B USD 1Y -11.6%
300406.SZ
300406.SZ • China
BSBE
12.14 CNY
1.06B USD 1Y -9.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
28.3% p.a.
Max Drawdown (5Y)
-63.5%
Sharpe Ratio (5Y)
-0.48
Beta Factor
0.07
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 63.3 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -63.5% in the extended horizon.
ende